Meanwhile, Davar et al. claimed that patients carrying PD1-resistant melanoma could benefit from a combinatory approach of FMT and anti-PD1 therapy primarily through modulating microbiota composition and reprogramming the immune tone (81). This evidence concerns the gene PDCD1 and melanoma.